SCHEMBL470348

SCHEMBL470348

Cc1nc2cc(-c3ccccc3)nn2c(-c2ccc(Cl)c(Cl)c2)c1C(OC(C)(C)C)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.59
CYP3A4 P08684 3/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
DPP4 P27487 1/20 0.41
TP53 P04637 2/20 0.40
MAPT P10636 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
HPGD P15428 3/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NFKB1 P19838 1/20 0.39
HTT P42858 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
PSIP1 O75475 1/20 0.39
KDM4E B2RXH2 3/20 0.38
MEN1 O00255 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL470359 0.93 NR1I2 (0.62) NR1I2CYP3A4CYP2C9CYP2C19DPP4
SCHEMBL470494 0.93 NR1I2 (0.62) NR1I2CYP3A4CYP2C9CYP2C19DPP4
SCHEMBL470315 0.91 NR1I2 (0.61) NR1I2CYP3A4CYP2C9CYP2C19DPP4
SCHEMBL12091025 0.90 NR1I2 (0.66) NR1I2CYP3A4CYP2C9CYP2C19TP53
SCHEMBL10174791 0.90 NR1I2 (0.60) NR1I2CYP3A4CYP2C9CYP2C19DPP4
SCHEMBL470405 0.90 NR1I2 (0.60) NR1I2CYP3A4CYP2C9CYP2C19DPP4
SCHEMBL12090950 0.89 NR1I2 (0.61) NR1I2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL461476 0.89 NR1I2 (0.63) NR1I2MAPTNPC1RAB9AHPGD
SCHEMBL10174452 0.89 NR1I2 (0.62) NR1I2CYP3A4CYP2C9CYP2C19TP53
SCHEMBL470488 0.88 NR1I2 (0.62) NR1I2CYP3A4CYP2C9CYP2C19DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS NR1I2 3085/4885CYP3A4 1719/4885CYP2C9 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.